Share through
St. Jude Research Logo
About Us
Care & Treatment
Research
Training
Get Involved
Ways to Give
St. Jude Research
WHY ST. JUDE
Back
WHY ST. JUDE
Robust Databases and Tools
Unparalleled Shared Resources
Translational Innovation
WHY ST. JUDE
DEPARTMENTS & LABS
Back
DEPARTMENTS & LABS
Departments
Labs
CENTERS & INITIATIVES
Back
CENTERS & INITIATIVES
Comprehensive Cancer Center
Institutional Initiatives
Global Impact on Infectious Disease
St. Jude Research Collaboratives
CENTERS & INITIATIVES
CAREERS
Search
When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures.
Home
Why St. Jude
Shared Resources & Core Facilities
Technology Licensing
Biologics
Biologics
Activation of Prodrugs by Carboxylesterase (SJ-98-0001)
Anti-GD2-BB-zeta Chimeric Receptor for Treating GD2+ Malignancies (SJ-13-0035)
Antibodies to Tim4 for use as an Immune Enhancer and Cancer Therapeutic (SJ-18-0006)
Association of Neuraminidase Regulated Exocytosis with Cancer Metastasis (SJ-11-0012)
B7-H3-CAR 41BB ligand co-stimulation for solid tumors (SJ-19-0014)
BCRP/ABCG2 as Stem Cell Marker (SJ-97-0016)
CD33 CAR (SJ-17-0010)
CD7 CAR placed in CD7neg memory cells (SJ-15-0020)
Chimeric gene and protein that can be used to create Optogranules: Light induced stress granules (SJ-18-0010)
Development and Optimization of a Serotype-Independent Method of Adeno-Associated Virus (AAV) Harvest and Purification (SJ-16-0036)
DNA Methylation Profile and Biomarkers for identifying functional T-cells (SJ-17-0002)
DNMT3a knockout CAR T cells with Antigen Specificity (for solid tumors) (SJ-19-0024)
Efficient generation of T-Cell Receptor (TCR) sequences in response to a variety of immune responses (SJ-19-0017)
Erythroid Specific Promoter for Hematopoietic Disorders (SJ-16-0040)
Extradomain-B Fibronectin (EDB)-targeted CAR Immune Cell Therapy (SJ-19-0029)
Fibcd1 to treat or prevent muscle wasting (SJ-20-0008)
Gene Therapy for Wiskott-Aldrich Syndrome (SJ-19-0012)
Generation of Therapeutic T Cell Receptors for Fibrolamellar Cancer (SJ-19-0046)
GMCSF.IL18 chimeric cytokine receptor for solid tumors (SJ-19-0028)
GRP78 targeted adoptive cell therapy for surface GRP78+ (pediatrics and adult) cancer (SJ-19-0050)
HMGA2 in Gene Therapy Vectors (SJ-16-0014)
Hybrid Compounds to treat Gastrointestinal Infections (SJ-14-0019/UTA 14-01)
IL35 Receptor (SJ-08-0039)
Immune Cells with DNMT3A Gene Modifications (SJ-16-0009)
Improved GD2 Ab for Neuroblastoma (SJ-17-0017)
Improved Method to Produce Proteins to Treat Lysosomal Storage Disorders (SJ-01-0020)
Interleukin-35 (IL-35) (SJ-06-0016)
MAGE-A11 Inhibitor for cancer (SJ-20-0033)
Method for Enhancing Recombinant Antibody Production (SJ-08-0032)
Method for predicting T-cell development stage (and therapy success) (SJ-19-0033)
Minimized Liver Specific Promoter for Improved Gene Expression in Gene Therapy Vectors (SJ-04-0024)
miRNAs for Treating Cerebral Ventricle Enlargement in Schizophrenia Patients (SJ-19-0039)
Myd88 and CD40 Costimulatory Domains for Chimeric Antigen Receptors (SJ-18-0021)
New Method for Differentiating T-cells (SJ-18-0019)
p53 Inhibitory Oligonucloeotides (SJ-09-0015)
Protease Serine 21 (PRSS21) Targeted Immunotherapies (SJ-18-0043)
Rapid Cloning of T Cell Receptors (TCRs) (SJ-16-0001)
REGNASE-1 Gene Knockout or BATF Overexpression for Improving T-cell Function (SJ-19-0027, SJ-20-0007)
Regulating p53 Translation and Function (SJ-05-0002)
RIPK3 Fusion Protein for Treating Cancer and Autoimmunity (SJ-12-0036)
Safety Test for Gene Therapy Vectors (SJ-15-0027)
Use of Amylase or Maltose to Treat or Prevent Neurodegeneration (SJ-20-0009)
Use of IL13 Promoter to Express Therapeutic Genes (SJ-18-0042)
For more information
Contact the
Office of Technology Licensing
:
Phone: (901) 595-2342
Fax: (901) 595-3148
OTL Intellectual Properties Newsletters
More Technologies
Antibodies for Basic Research
Biologics
Diagnostics
Drugs
Drug Discovery & Development Tools
Vaccines